Heparin-induced thrombocytopenia: Frequency and pathogenesis

Pathophysiology of Haemostasis and Thrombosis

Volumn 35, Issue 1-2, 2006, Pages

  Greinacher, Andreas ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FONDAPARINUX; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; POLYANION; THROMBOCYTE FACTOR 4;

ANTIBODY SPECIFICITY; ANTIGEN STRUCTURE; AUTOIMMUNITY; COMPLEX FORMATION; CONFERENCE PAPER; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNITY; IMMUNOASSAY; LABORATORY TEST; LEUKOCYTE; MORBIDITY; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

EID: 33748446112     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093542     Document Type: Conference Paper

References (90)

1. King DJ, Kelton JG: Heparin-associated thrombocytopenia. Ann Intern Med 1984;100:535-540.
2. Greinacher A, Eichler P, Lietz T, Warkentin TE: Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 2005;106:2921-2922.
3. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
4. Warkentin TE, Kelton JG: A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507.
5. Warkentin TE: Current agents for the treatment of patients with heparin-induced thrombocytopenia. Curr Opin Pulm Med 2002;8:405-412.
6. Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A: The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003;101:2955-2959.
7. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P: Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005;94:132-135.
8. Warkentin TE: Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998;35:9-16.
9. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95-96.
10. Greinacher A, Michels I, Schafer M, Kiefel V, Mueller-Eckhardt C: Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan. Br J Haematol 1992;81:252-254.
11. Rosenthal MA, Rischin D, McArthur G, Ribbons K, Chong B, Fareed J, Toner G, Green MD, Basser RL: Treatment with the novel antiangiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann Oncol 2002;13:770-776.
12. Li ZQ, Liu W, Park KS, Sachais BS, Arepally GM, Cines DB, Poncz M: Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 2002;99:1230-1236.
13. Visentin GP, Liu CY, Aster RH: Molecular immunopathogenesis of Heparin-induced thrombocytopenia; in Warkentin TE, Greinacher A, (eds): Heparin-induced thrombocytopenia. New York, Marcel Dekker, 2004, pp 179-196.
14. Ziporen L, Li ZQ, Park KS, Sabnekar P, Liu WY, Arepally G, Shoenfeld Y, Kieber-Emmons T, Cines DB, Poncz M: Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998;92:3250-3259.
15. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C: Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-251.
16. Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG: Heparin-induced thrombocytopenia: laboratory studies. Blood 1988;72:925-930.
17. Warkentin TE, Chong BH, Greinacher A: Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998;79:1-7.
18. Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Potzsch B: Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80.
19. Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B, Eichler P, Volpel H, Potzsch B, Luz M: Lepirudin (Recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-593.
20. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M: Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-851.
21. Ponzc M: Proceeding 2006.
22. Greinacher A, Michels I, Mueller-Eckhardt C: Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992;67:545-549.
23. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C: Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995;74:886-892.
24. Wolf H, Nowack H, Wick G: Detection of antibodies interacting with glycosaminoglycan polysulfate in patients treated with heparin or other polysulfated glycosaminoglycans. Int Arch Allergy Appl Immunol 1983;70:157-163.
25. Visentin GP, Ford SE, Scott JP, Aster RH: Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-88.
26. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-3239.
27. Alban S, Greinacher A: Role of sulphated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia; in Warkentin TE, Greinacher A, (eds): Heparin-Induced Thrombocytopenia. New York, Marcel Dekker, Inc., 2004, pp 197-221.
28. Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS: Ultralarge complexes of heparin and PF4 are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2004;105:131-138.
29. Warkentin T.E., Cook RJ, Marder VJ, Kelton JG: Comparison of heparin-induced thrombocytopenia antibody (HIT-Ab) generation and in vitro cross-reactivity after elective hip or knee replacement surgery in patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.; 2003.
30. Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R: Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol 2002;118:1137-1142.
31. Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y: Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99:2530-2536.
32. Mikhailov D, Young HC, Linhardt RJ, Mayo KH: Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia. J Biol Chem 1999;274:25317-25329.
33. van Boeckel C, Petitou M: The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem [Int Ed Engl] 1993;32:1671-1690.
34. Elalamy I, Lecrubier C, Potevin F, Abdelouahed M, Bara L, Marie JP, Samama M: Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 1995;74:1384-1385.
35. Amiral J, Lormeau JC, Marfaing-Koka A, Vissac AM, Wolf M, Boyer-Neumann C, Tardy B, Herbert JM, Meyer D: Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997;8:114-117.
36. Ahmad S, Jeske WP, Walenga JM, Hoppensteadt DA, Wood JJ, Herbert JM, Messmore HL, Fareed J: Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 1999;5:259-266.
37. Kovacs MJ: Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005;93:999-1000.
38. Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M, Herault JP, Cariou R, Herbert JM: Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005;105:139-144.
39. Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, Greinacher A, Kelton JG: Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005;106:3791-3796.
40. Bauer KA, Eriksson BI, Lassen MR, Turpie AG: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310.
41. Turpie AG, Bauer KA, Eriksson BI, Lassen MR: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-1726.
42. Pouplard C, Couvret C, Regina S, Gruel Y: Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux. J Thromb Haemost 2005;3:2813-2815.
43. Warkentin TE, Kelton JG: Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001;135:502-506.
44. Rice L, Attisha WK, Drexler A, Francis JL: Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002;136:210-215.
45. Prechel MM, McDonald MK, Jeske WP, Messmore HL, Walenga JM: Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. J Thromb Haemost 2005;3:2168-2175.
46. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M: Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006;107:2346-2353.
47. Polgar J, Eichler P, Greinacher A, Clemetson KJ: Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood 1998;91:549-554.
48. Greinacher A, Gopinadhan M, Günther JU, Omer-Adam MA, Strobel U, Warkentin TE, Papastavrou G, Weitschies W, Helm C: The Molecular Structure of the Antigen in Heparin-induced Thrombocytopenia.J Thromb Haemost 2005;3:OR217(Abstract)
49. Cines DB, Tomaski A, Tannenbaum S: Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;316:581-589.
50. Greinacher A, Mockel M, Mueller-Eckhardt C: Suppression of FcRII by intravenously administerd IgG is dependent of preparation procedures of immunoglobulins. Beitr Infusionsther Transfusionsmed 1994;32:211-213.
51. Blank M, Shoenfeld Y, Tavor S, Praprotnik S, Boffa MC, Weksler B, Walenga MJ, Amiral J, Eldor A: Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002;14:121-129.
52. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-812.
53. Asmis L, Demming C, Arepally G, Rade J: The Interaction of Platelets and Endothelial Cells Modulate the Procoagulant/Anticoagulant Balance in Heparin-Induced Thrombocytopenia; 2003.
54. Herbert JM, Savi P, Jeske WP, Walenga JM: Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost 1998;80:326-331.
55. Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, Kelton JG: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-3699.
56. Pearson JD: Endothelial cell function and thrombosis. Baillieres Best Pract Res Clin Haematol 1999;12:329-341.
57. Blann AD, Seigneur M, Steiner M, Boisseau MR, McCollum CN: Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 1997;27:916-921.
58. Blank M, Eldor A, Tavor S, Ziporen L, Cines DB, Arepally G, Afek A, Shoenfeld Y: A mouse model for heparin-induced thrombocytopenia. Semin Hematol 1999;36:12-16.
59. Reilly MP, Taylor SM, Hartman NK, Arepally GM, Sachais BS, Cines DB, Poncz M, McKenzie SE: Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood 2001;98:2442-2447.
60. Carlsson LE, Santoso S, Baurichter G, Kroll H, Papenberg S, Eichler P, Westerdaal NA, Kiefel V, van de Winkel JG, Greinacher A: Heparin-induced thrombocytopenia: new insights into the impact of the FcgammaRIIa-R-H131 polymorphism. Blood 1998;92:1526-1531.
61. Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y: Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001;97:3300-3302.
62. Aziz KA, Cawley JC, Zuzel M: Platelets prime PMN via released PF4: mechanism of priming and synergy with GM-CSF. Br J Haematol 1995;91:846-853.
63. Jy W, Mao WW, Horstman L, Tao J, Ahn YS: Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol Dis 1995;21:217-231.
64. Khairy M, Lasne D, Amelot A, Crespin M, Rendu F, Aiach M, Bachelot-Loza C: Polymorphonuclear leukocyte and monocyte activation induced by plasma from patients with heparin-induced thrombocytopenia in whole blood. Thromb Haemost 2004;92:1411-1419.
65. Khairy M, Lasne D, Brohard-Bohn B, Aiach M, Rendu F, Bachelot-Loza C: A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Formation of leukocyte-platelet aggregates. Thromb Haemost 2001;85:1090-1096.
66. Amiral J, Meyer D: Heparin-dependent antigens in heparin-induced antibodies.; in Warkentin TE, Greinacher A, (eds): Heparin-induced thrombocytopenia. New York, Marcel Dekker, 2004, pp 165-178.
67. Chong BH, Pilgrim RL, Cooley MA, Chesterman CN: Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood 1993;81:988-993.
68. Warkentin TE: Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Saf 1997;17:325-341.
69. Greinacher A: Heparin-induced thrombocytopenia - pathogenesis and treatment. Thromb Haemost 1999;82 Suppl 1:148-156.
70. Amiral J, Wolf M, Fischer A, Boyer-Neumann C, Vissac A, Meyer D: Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996;92:954-959.
71. Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R: Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001;113:886-890.
72. Lindhoff-Last E, Eichler P, Stein M, Plagemann J, Gerdsen F, Wagner R, Ehrly AM, Bauersachs R: A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res 2000;97:387-393.
73. Suh JS, Malik MI, Aster RH, Visentin GP: Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997;54:196-201.
74. Warkentin T, Sheppard J, Moore J, Moore K, Sigouin C, Kelton J: Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2006; in press.
75. Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A: Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006.
76. Schenk S, El-Banayosy A, Prohaska W, Arusoglu L, Morshuis M, Koester-Eiserfunke W, Kizner L, Murray E, Eichler P, Koerfer R, Greinacher A: Heparin-induced Thrombocytopenia in Patients on Mechanical Circulatory Support. Journal of Thoracic and cardiovascular surgery. In press.
77. Amiral J, Marfaing-Koka A, Wolf M, Alessi MC, Tardy B, Boyer-Neumann C, Vissac AM, Fressinaud E, Poncz M, Meyer D: Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996;88:410-416.
78. Regnault V, de Maistre E, Carteaux JP, Gruel Y, Nguyen P, Tardy B, Lecompte T: Platelet activation induced by human antibodies to interleukin-8. Blood 2003;101:1419-1421.
79. Martel N, Lee J, Wells PS: Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005;106:2710-2715.
80. Warkentin TE, Greinacher A: Unfractionated, low-molecular-weight heparin and risk of HIT: are medical patients different? [Inside Blood Commentrary on BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low molecular weight heparin. A prospective cohort study. Blood 2005;106:2931-2932.
81. Prandoni P, Siragusa S, Girolami B, Fabris F: The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005;106:3049-3054.
82. Pohl C, Kredteck A, Bastians B, Hanfland P, Klockgether T, Harbrecht U: Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin. Neurology 2005;64:1285-1287.
83. Greer IA, Nelson-Piercy C: Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;106:401-407.
84. Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia: recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:311S-337S.
85. Tholl U, Greinacher A, Overdick K, Anlauf M: Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrol Dial Transplant 1997;12:2750-2755.
86. Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN: Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005;93:63-69.
87. Klenner AF, Lubenow N, Raschke R, Greinacher A: Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb Haemost 2004;91:719-724.
88. Warkentin TE, Cook DJ: Heparin, low molecular weight heparin, and heparin-induced thrombocytopenia in the ICU. Crit Care Clin 2005;21:513-529.
89. Crowther MA, Cook DJ, Meade MO, Griffith LE, Guyatt GH, Arnold DM, Rabbat CG, Geerts WH, Warkentin TE: Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005;20:348-353.
90. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y: Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005;128:837-841.